RT Journal Article
SR Electronic
T1 618 Phase 1 clinical trial evaluating the safety, biologic and anti-tumor activity of the novel STING agonist IMSA101 administered both as monotherapy and in combination with PD-(L)1 checkpoint inhibitors
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP A704
OP A704
DO 10.1136/jitc-2023-SITC2023.0618
VO 11
IS Suppl 1
A1 Moser, Justin C
A1 Alistar, Angela
A1 Cohen, Ezra
A1 Garmey, Edward
A1 Kazmi, Syed
A1 Mooneyham, Teresa
A1 Sun, Lijun
A1 Yap, Timothy
A1 Mahalingam, Devalingam
YR 2023
UL http://jitc.bmj.com/content/11/Suppl_1/A704.abstract
AB Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.